Cart
sales@molnova.com
Gypsogenin
CAS No. 639-14-5
Gypsogenin( 639-14-5 )
Catalog No. M24652 CAS No. 639-14-5
Gypsogenin is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 299 | In Stock |
|
| 10MG | 444 | In Stock |
|
| 25MG | 709 | In Stock |
|
| 50MG | 1008 | In Stock |
|
| 100MG | 1341 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGypsogenin
-
NoteResearch use only, not for human use.
-
Brief DescriptionGypsogenin is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.
-
DescriptionGypsogenin is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.
-
In Vitro——
-
In Vivo——
-
Synonyms639-14-5
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorABL1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number639-14-5
-
Formula Weight470.69
-
Molecular FormulaC30H46O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (53.11 mM)
-
SMILESCC(C)(CC1)C[C@H]2C3=CC[C@H]([C@@](C)(CC[C@@H]4O)[C@@H](CC5)[C@]4(C)C=O)[C@]5(C)[C@]3(C)CC[C@]12C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Heller L , Schwarz S , Weber B A , et al. Gypsogenin Derivatives: An Unexpected Class of Inhibitors of Cholinesterases[J]. Archiv Der Pharmazie, 2015, 347(10):707-716.
molnova catalog
related products
-
Imatinib impurities3
Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.
-
ABL-IN-29
ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.
-
DCC-2036
DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4 nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively.
